Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATLCAR.κ.28
- Development stage
- Unknown
- Lead developer
- UNC Lineberger Comprehensive Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ATLCAR.κ.28 is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the UNC Lineberger Comprehensive Cancer Center. It is designed to target the kappa (κ) light chain of human immunoglobulins, which is expressed on the surface of malignant B cells in certain types of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). The CAR construct incorporates an anti-kappa light chain single-chain variable fragment (scFv) linked to a CD28 co-stimulatory endodomain and the CD3ζ signaling domain. By targeting the light chain rather than a pan-B-cell marker like CD19, the therapy aims to selectively eliminate the clonal malignant B-cell population while potentially sparing B cells expressing the lambda (λ) light chain, thereby reducing the severity of humoral immunodeficiency. It is currently being evaluated in Phase 1 clinical trials for relapsed or refractory kappa-positive B-cell malignancies.
- Other names
- Autologous T Lymphocyte Chimeric Antigen Receptor kappa.28anti-kappa CAR-T cells
02
Targets
CD28 (Cluster of Differentiation 28)Immunoglobulin light chainCD247 (T-cell surface glycoprotein CD3 epsilon chain)
Beyond the preview
Go deeper on ATLCAR.κ.28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATLCAR.κ.28.